Explore cjc-1295 dac calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized cjc-1295 dac calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
CJC-1295 with DAC is the long-acting GHRH-analog research peptide most often sourced for GH-axis protocols where a single weekly dose is preferred. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
Like the no-DAC variant, CJC-1295 DAC binds the GHRH receptor on pituitary somatotropes; the albumin tether converts what would be a brief, pulsatile signal into a continuous receptor exposure. Continuous activation raises baseline IGF-1 substantially but partially flattens the body's natural GH-pulse architecture — a pharmacologic difference that distinguishes it from the no-DAC variant clinicians use to preserve endogenous pulsatility.[2]
A Phase 1 single-ascending-dose study in healthy adults (Teichman et al., JCEM 2006) documented sustained ~1.5–3× elevation of IGF-1 lasting 6+ days after a single subcutaneous injection.[2] ConjuChem advanced CJC-1295 into Phase 2 trials for GH-deficient adults and pediatric short stature in 2007–2008; the program was halted following the death of a participant during a Phase 2 lipodystrophy trial.[3] No Phase 3 program followed and CJC-1295 has no active sponsor today.
Not FDA-approved. Clinical development halted after a 2008 Phase 2 safety event. Placed on the FDA 503A "do not compound" interest list in September 2023.
CJC-1295 DAC has a reported half-life of ~6–8 days. The pharmacokinetic reference models an interval of once or twice weekly; this is not a measured community cadence or a dosing recommendation. The DAC version binds to blood proteins and lasts about a week, so it builds to a steady level over several weeks and provides a constant GH-releasing signal. Pharmacokinetic source: Teichman et al. J Clin Endocrinol Metab 2006 (CJC-1295 with DAC). It is catalogued under Muscle Peptides on WPA.
396 CJC-1295 DAC reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
Standalone CJC-1295 DAC is the GHRH side of a stack run on its own, and the molecule that makes it possible is the drug-affinity-complex (DAC) linker ConjuChem engineered onto the parent Modified GRF 1-29 backbone in the early 2000s. The pivotal pharmacokinetic study is Teichman et al., Journal of Clinical Endocrinology & Metabolism 2006 — "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults" — which showed that a single subcutaneous dose of CJC-1295 DAC produced a sustained elevation in IGF-1 of up to 28 days, with mean GH levels rising to roughly 8-fold over baseline at steady state and a half-life on the order of 5-8 days. The mechanism is straight albumin-binding pharmacology: the maleimidopropionic acid linker covalently attaches to albumin Cys34 immediately after injection, and the resulting albumin-conjugate behaves as a slow-release depot that produces continuous GHRH-receptor exposure for the better part of a week — fundamentally different from the ~30-minute half-life of the No DAC variant (Modified GRF 1-29) and well-suited to a once-weekly or every-few-days dosing cadence rather than the multi-daily schedule the short-acting GHRH analogs require.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.